Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.<\/p>\n
Novo Nordisk A\/S on Monday shared topline results from its STEP Young Phase 3 clinical trial evaluating once-weekly semaglutide in children aged 6 to under 12 with obesity.<\/p>\n
The study achieved its primary endpoint, demonstrating a significantly higher reduction in body mass index (BMI) at week 68 among pediatric patients receiving semaglutide compared to those receiving a placebo.<\/p>\n
STEP Young Trial Yields Significant BMI Reductions<\/p>\n
At the start of the study, over 85% of participating children presented with severe obesity, categorized as class II or class III.<\/p>\n
Don’t Miss:<\/p>\n
By week 68, 40.4% of participants treated with once-weekly subcutaneous semaglutide were no longer classified as having obesity, bringing their BMI down to overweight or normal weight levels.<\/p>\n
In contrast, 0% of the children in the placebo group achieved non-obese status.<\/p>\n
The trial’s findings offer potential hope for an age bracket facing rising obesity rates alongside limited clinically evaluated or approved treatment choices when diet and exercise alone prove insufficient.<\/p>\n
Both intervention arms in the study received ongoing lifestyle modifications, which included a reduced-calorie diet and increased physical activity.<\/p>\n
See Also: Avoid the #1 Investing Mistake: How Your ‘Safe’ Holdings Could Be Costing You Big Time<\/a><\/p>\n Safety Profile Aligns With Previous Studies<\/p>\n The safety and tolerability profile of semaglutide in the STEP Young trial aligned with findings from earlier adult and pediatric trials involving semaglutide and liraglutide.<\/p>\n Researchers identified no new safety issues, and the treatment raised no safety concerns regarding the growth or pubertal development of the young patients.<\/p>\n Image via Shutterstock<\/p>\n Read Next:\u00a0<\/p>\n Building Wealth Across More Than Just the Market<\/p>\n Building a resilient portfolio means thinking beyond a single asset or market trend. Economic cycles shift, sectors rise and fall, and no one investment performs well in every environment. That’s why many investors look to diversify with platforms that provide access to real estate, fixed-income opportunities, precious metals, and even self-directed retirement accounts. By spreading exposure across multiple asset classes, it becomes easier to manage risk, capture steady returns, and create long-term wealth that isn’t tied to the fortunes of just one company or industry.<\/p>\n Arrived<\/p>\n Backed by Jeff Bezos, Arrived Homes makes real estate investing accessible with a low barrier to entry. Investors can buy fractional shares of single-family rentals and vacation homes starting with as little as $100<\/a>. This allows everyday investors to diversify into real estate, collect rental income, and build long-term wealth without needing to manage properties directly.<\/p>\n Qnetic<\/p>\n As electricity demand rises alongside AI, data centers, and renewable energy, long-duration energy storage is becoming increasingly important. Qnetic is developing a kinetic energy storage system designed to provide long-lasting, chemical-free electricity storage<\/a>, <\/a>offering investors exposure to the infrastructure supporting a more resilient and reliable power grid.<\/p>\n EquityMultiple\u00a0<\/p>\n For accredited investors looking beyond stocks and bonds, EquityMultiple provides access to vetted commercial real estate deals starting at $5,000<\/a>,<\/a> with only ~5% of opportunities passing their due diligence process.\u00a0<\/p>\n FarmTogether<\/p>\n Farmland has historically held its value through market volatility and delivered returns uncorrelated to stocks and bonds. For accredited investors, FarmTogether offers direct access to high-quality U.S. farmland starting at $15,000<\/a> \u2014 fully managed, with no landlord headaches.<\/p>\n Fundrise<\/p>\n